Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

ABSTRACT: The mechanisms underlying the susceptibility of individuals with caspase recruitment domain 15 (CARD15) mutations and corresponding abnormalities of nucleotide-binding oligomerization domain 2 (NOD2) protein to Crohn disease are still poorly understood. One possibility is based on previous studies showing that muramyl dipeptide (MDP) activation of NOD2 negatively regulates TLR2 responses and that absence of such regulation leads to heightened Th1 responses. We now report that administration of MDP protects mice from the development of experimental colitis by downregulating multiple TLR responses, not just TLR2. The basis of these in vivo findings was suggested by in vitro studies of DCs, in which we showed that prestimulation of cells with MDP reduces cytokine responses to multiple TLR lig

SUBMITTER: Watanabe T 

PROVIDER: S-EPMC2176188 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature